12. Mackay AJ, Hurst JR. COPD exacerbations: causes, prevention, and treatment. Immunol Allergy Clin North Am, 2013, 33(1): 95-115.
[3]
13. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J, 2004, 23(6): 932-946.
[4]
14. Miller M. Hyponatremia and arginine vasopressin dysregulation: mechanisms, clinical consequences, and management. J Am Geriatr Soc, 2006, 54(2): 345-353.
[5]
15. Jochberger S, Morgenthaler NG, Mayr VD, et al. Copeptin and arginine vasopressin concentrations in critically ill patients. J Clin Endocrinol Metab, 2006, 91(11): 4381-4386.
[6]
16. Valli G, Fedeli A, Antonucci R, et al. Water and sodium imbalance in COPD patients. Monaldi Arch Chest Dis, 2004, 61(2):112-116.
[7]
17. Christ-Crain M, Mailer B. Biomarkers in respiratory, tract infections:diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J, 2007, 30(3): 556-573.
1. Gold Executive Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (Revised 2013) [EB/OL]. [2013-11-20]. Available at http://goldcopd.org.
4. Morgenthaler NG, Mailer B, Struck J, et al. Copeptin, a stable peptide of the arginine vasopressin precursor is elevated in hemorrhagic and septic shock. Shock, 2007, 28(2): 219-226.
[13]
5. Stolz D, Christ-Crain M, Morgenthaler NG, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest, 2007, 131(4): 1058-1067.
[14]
6. Neuhold S, Huelamann M, Strunk G, et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol, 2008, 52(4): 266-272.
19. Morgenthaler NG, Struck J, Alonso C, et al. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem, 2006, 52(1): 112-119.
